Neuromyelitis optica and neuromyelitis optica spectrum disorders

Current Opinion in Neurology

Volumn 30, Issue 3, 2017, Pages 208-215

  Marignier, Romain ^a,b,c   Calvo, Alvaro Cobo ^a,b   Vukusic, Sandra ^a,b,c  

^a HÔPITAL NEUROLOGIQUE   (France)

^b INSERM   (France)

^c Observatoire Français de la Sclérose en Plaques OFSEP   (France)

Author keywords

Aquaporin 4; Auto antibodies; Myelin oligodendrocyte glycoprotein; Neuromyelitis optica spectrum disorders; Seronegative

Indexed keywords

IMMUNOGLOBULIN G; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; BLOCKING ANTIBODY;

CLINICAL FEATURE; ETHNIC DIFFERENCE; HUMAN; LARGE SCALE PRODUCTION; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); MYELOOPTIC NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY;

ANIMALS; ANTIBODIES, BLOCKING; HUMANS; IMMUNOGLOBULIN G; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NEUROMYELITIS OPTICA; PREVALENCE;

EID: 85015706769     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000455     Document Type: Review

References (110)

1. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53:1107-1114.
2. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125:1450-1461.
3. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364:2106-2112.
4. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6:805-815.
5. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol 2012; 11:535-544.
6. Fujihara K. Neuromyelitis optica and astrocytic damage in its pathogenesis. J Neurol Sci 2011; 306:183-187.
7. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66:1485-1489.
8. Bizzoco E, Lolli F, Repice AM, et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 2009; 256:1891-1898.
9. Asgari N, Lillevang ST, Skejoe HPB, et al. A population-based study of neuromyelitis optica in Caucasians. Neurology 2011; 76:1589-1595.
10. Nagaishi A, Takagi M, Umemura A, et al. Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatry 2011; 82:1360-1364.
11. Mealy MA, Wingerchuk DM, Greenberg BM, et al. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol 2012; 69:1176-1180.
12. Cossburn M, Tackley G, Baker K, et al. The prevalence of neuromyelitis optica in South East Wales. Eur J Neurol 2012; 19:655-659.
13. Jacob A, Panicker J, Lythgoe D, et al. The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. J Neurol 2013; 260:2134-2137.
14. Misu T, Fujihara K, Nakashima I, et al. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005; 65:1479-1482.
15. Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006; 63:390-396.
16. Viegas S, Weir A, Esiri M, et al. Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2009; 80:679-682.
17. Popescu BFG, Lennon VA, Parisi JE, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 2011; 76:1229-1237.
18. Kim W, Kim S-H, Lee SH, et al. Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder. Mult Scler 2011; 17:1107-1112.
19. Kremer L, Mealy M, Jacob A, et al. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler 2014; 20:843-847.
20. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006; 59:566-569.
21. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008; 70:2197-2200.
22. Collongues N, Marignier R, Zephir H, et al. Neuromyelitis optica in France. A multicenter study of 125 patients Neurology 2010; 74:736-742.
23. Collongues N, Cabre P, Marignier R, et al. A benign form of neuromyelitis optica: does it exist? Arch Neurol 2011; 68:918-924.
24. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012; 135:1834-1849.
25. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation 2012; 9:14.
26. Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007; 130:1224-1234.
27. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130:1194-1205.
28. Misu T, Höftberger R, Fujihara K, et al. Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol 2013; 125:815-827.
29. Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007; 69:2221-2231.
30. Sabater L, Giralt A, Boronat A, et al. Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. J Neuroimmunol 2009; 215:31-35.
31. Zhang H, Bennett JL, Verkman AS. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol 2011; 70:943-954.
32. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009; 66:630-643.
33. Kinoshita M, Nakatsuji Y, Kimura T, et al. Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun 2009; 386:623-627.
34. Saadoun S, Waters P, Bell BA, et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010; 133:349-361.
35. Geis C, Ritter C, Ruschil C, et al. The intrinsic pathogenic role of auto-antibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model. Exp Neurol 2015; 265:8-21.
36. Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic antiaquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009; 66:617-629.
37. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes antiaquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 2011; 108:3701-3706.
38. Vincent T, Saikali P, Cayrol R, et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol 2008; 181:5730-5737.
39. Shimizu F, Sano Y, Takahashi T, et al. Sera from neuromyelitis optica patients disrupt the blood-brain barrier. J Neurol Neurosurg Psychiatry 2012; 83:288-297.
40. Takano R, Misu T, Takahashi T, et al. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010; 75:208-216.
41. Hinson SR, Romero MF, Popescu BFG, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A 2012; 109:1245-1250.
42. Rossi A, Ratelade J, Papadopoulos MC, et al. Consequences of NMO-IgG binding to aquaporin-4 in neuromyelitis optica. Proc Natl Acad Sci U S A 2012; 109:E1511.
43. Vaknin-Dembinsky A, Brill L, Kassis I, et al. T-cell reactivity against AQP4 in neuromyelitis optica. Neurology 2012; 79:945-946.
44. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 2012; 72:53-64.
45. Linhares UC, Schiavoni PB, Barros PO, et al. The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients. J Clin Immunol 2013; 33:179-189.
46. Sharma R, Fischer M-T, Bauer J, et al. Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathol 2010; 120:223-236.
47. Marignier R, Nicolle A, Watrin C, et al. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain 2010; 133:2578-2591.
48. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261:1-16.
49. Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 2012; 1:180-187.
50. Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler J 2015; 21:845-853.
51. Miyamoto K. Epidemiology of neuromyelitis optica. Nihon Rinsho 2015; 73 (SUPPL. 7):260-264.
52. Flanagan EP, Cabre P, Weinshenker BG, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol 2016; 79:775-783.
53. Van Pelt D, Wong YY, Ketelslegers IA, et al. Incidence of AQP4-IgG seropositive neuromyelitis optica spectrum disorders in the Netherlands: about one in a million. MSJ Exp Transl Clin 2016; 2:1-4.
54. Yamaguchi Y, Torisu H, Kira R, et al. A nationwide survey of pediatric acquired demyelinating syndromes in Japan. Neurology 2016; 87:2006-2015.
55. Chitnis T, Ness J, Krupp L, et al. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology 2016; 86:245-252.
56. Borisow N, Kleiter I, Gahlen A, et al. Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. Mult Scler 2016; pii: 1352458516671203.
57. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85:177-189.
58. Sánchez Gomar I, Díaz Sánchez M, Uclés Sánchez AJ, et al. An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumab. BMC Neurol 2014; 14:139.
59. Cohen M, De Sèze J, Marignier R, et al. False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients. Mult Scler 2016; 22:1231-1234.
60. Waters P, Reindl M, Saiz A, et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2016; 87:1005-1015.
61. Hamid SH, Elsone L, Mutch K, et al. The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates. Mult Scler Published Online First 2016; 23:228-233.
62. Hyun J-W, Jeong IH, Joung A, et al. Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder. Neurology 2016; 86:1772-1779.
63. Höftberger R, Sepulveda M, Armangue T, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 2015; 21:866-874.
64. Sepúlveda M, Armangué T, Sola-Valls N, et al. Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm 2016; 3:e225.
65. Uzawa A, Mori M, Uchida T, et al. Seronegative neuromyelitis optica spectrum disorder patients diagnosed using new diagnostic criteria. Mult Scler 2016; 22:1371-1375.
66. Juryńczyk M, Weinshenker B, Akman-Demir G, et al. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. J Neurol 2016; 263:140-149.
67. Ito S, Mori M, Makino T, et al. 'Cloud-like enhancement' is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol 2009; 66:425-428.
68. Yonezu T, Ito S, Mori M, et al. 'Bright spotty lesions' on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis. Mult Scler 2014; 20:331-337.
69. Uzawa A, Mori M, Ito M, et al. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol 2009; 256:2082-2084.
70. Hinson SR, Lennon VA, Pittock SJ. Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders. In: Handbook of Clinical Neurology 2016. 377-403.
71. Asgari N, Berg CT, Mørch MT, et al. Cerebrospinal fluid aquaporin-4-immunoglobulin G disrupts blood brain barrier. Ann Clin Transl Neurol 2015; 2:857-863.
72. Marignier R, Ruiz A, Cavagna S, et al. Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid. J Neuroinflammation 2016; 13:111.
73. Herwerth M, Kalluri SR, Srivastava R, et al. In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis opticarelated pathology. Ann Neurol 2016. doi:10.1002/ana.24630.
74. Weil MT, Möbius W, Winkler A, et al. Loss of myelin basic protein function triggers myelin breakdown in models of demyelinating diseases. Cell Rep 2016; 16:314-322.
75. Zamvil SSSA. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2015; 2:e62.
76. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82:474-481.
77. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014; 71:276-283.
78. Kim S-M, Woodhall MR, Kim J-S, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm 2015; 2:e163.
79. van Pelt ED, Wong YYM, Ketelslegers IA, et al. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands. Eur J Neurol Published Online First 2016; 23:580-587.
80. Pandit L, Sato DK, Mustafa S, et al. Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India. MSJ Exp Transl Clin 2016; 2:1-5.
81. Cobo-Calvo a, Sepulveda M, Bernard-Valnet R, et al. Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: clinical and prognostic implications. Mult Scler J 2016; 22:312-319.
82. Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016; 13:280.
83. Sepúlveda M, Armangue T, Martinez-Hernandez E, et al. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J Neurol 2016; 263:1349-1360.
84. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010; 17:1019-1032.
85. Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses. Ann Neurol 2016; 79:206-216.
86. Abboud H, Petrak A, Mealy M, et al. Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler 2016; 22:185-192.
87. Weinshenker BG. What is the optimal sequence of rescue treatments for attacks of neuromyelitis optica spectrum Disorder? Ann Neurol 2016; 79:204-205.
88. Yamasaki R, Matsushita T, Fukazawa T, et al. Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica. Mult Scler 2016; 22:1337-1348.
89. Absoud M, Gadian J, Hellier J, et al. Protocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). BMJ Open 2015; 5:e008312.
90. Grünewald B, Bennett JL, Toyka KV, et al. Efficacy of polyvalent human immunoglobulins in an animal model of neuromyelitis optica evoked by intrathecal anti-aquaporin 4 antibodies. Int J Mol Sci 2016; 17:pii: E1407.
91. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008; 65:1443-1448.
92. Greenberg BM, Graves D, Remington G, et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler J 2012; 18:1022-1026.
93. Kim S-H, Huh S-Y, Lee SJ, et al. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 2013; 70:1110-1117.
94. Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011; 77:659-666.
95. Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, et al. Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 2010; 67:1131-1136.
96. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009; 66:1128-1133.
97. Xu Y, Wang Q, Ren H-T, et al. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: a prospective cohort study. J Neurol Sci 2016; 370:224-228.
98. Jeong IH, Park B, Kim S-H, et al. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler 2016; 22:329-339.
99. Chen H, Qiu W, Zhang Q, et al. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. Eur J Neurol Published Online First 2017; 24:219-226.
100. Montcuquet A, Collongues N, Papeix C, et al. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler 2016; pii: 1352458516678474.
101. Zéphir H, Bernard-Valnet R, Lebrun C, et al. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol 2015; 262:2329-2335.
102. Collongues N, Brassat D, Maillart E, et al. Efficacy of rituximab in refractory neuromyelitis optica. Mult Scler Published Online First 2016; 22:955-999.
103. Radaelli M, Moiola L, Sangalli F, et al. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Mult Scler 2016; 22:511-519.
104. Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders. JAMA Neurol 2016; 73:1342.
105. Tradtrantip L, Zhang H, Saadoun S, et al. Antiaquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 2012; 71:314-322.
106. Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 2014; 82:1302-1306.
107. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013; 12:554-562.
108. Mealy MA, Shin K, John G, et al. Bevacizumab is safe in acute relapses of neuromyelitis optica. Clin Exp Neuroimmunol 2015; 6:413-418.
109. Steinman L, Bar-Or A, Behne JM, et al. Restoring immune tolerance in neuromyelitis optica: Part I. Neurol Neuroimmunol neuroinflammation 2016; 3:e276.
110. Bar-Or A, Steinman L, Behne JM, et al. Restoring immune tolerance in neuromyelitis optica: Part II. Neurol Neuroimmunol neuroinflammation 2016; 3:e277.